Upadacitinib is selective for JAK1 and is approved for the treatment of rheumatoid arthritis, psoriatic arthropathy, axial spondyloarthritis, atopic dermatitis, ulcerative dermatitis and Crohn's disease (166). Here, JAK1 is linked to psoriatic arthritis.